Revlimid Does Not Increase The Risk Of AML Progression In Myelodysplastic Syndromes Patients (ASH 2010)
Published: Dec 27, 2010 10:14 am
French researchers found that treatment of lower-risk myelodysplastic syndromes patients with Revlimid does not increase the risk of progression to acute myeloid leukemia or decrease survival compared to similar patients not treated with Revlimid.
Dr. Lionel Ades of the Groupe Francophone des Myelodysplasies in France presented the results at the 52nd annual meeting of the American Society of Hematology in Orlando earlier this month.
Revlimid (lenalidomide) is approved in the U.S. to treat lower-risk myelodysplastic syndromes (MDS) patients with the chromosomal abnormality deletion 5q who are dependent on red blood cell transfusions.
However, there was concern in Europe that Revlimid may be associated with an increased risk of progression to acute myeloid leukemia (AML).
To address that concern, the French researchers analyzed data of 95 transfusion-dependent lower-risk MDS patients with the chromosomal abnormality deletion 5q, as well as 99 patients with similar disease characteristics who did not receive treatment with Revlimid, to assess the risk of AML progression and overall survival for both groups.
Disease score, gender, age at diagnosis, and genetic abnormalities were assessed for each Revlimid-treated patient, and 71 of them were paired up with a close match from the group without Revlimid for comparison.
The researchers found that patients receiving Revlimid had a lower risk of AML progression. After four years, 9 percent of the patients who received treatment with Revlimid had progressed to AML compared to 16 percent of patients who did not receive Revlimid.
In addition, treatment with Revlimid did not decrease overall survival in patients receiving Revlimid. Patients receiving Revlimid survived for 150 months compared to 73 months for patients who did not receive Revlimid.
- Higher-Risk MDS Patients May Benefit From The Addition Of Revlimid To Vidaza Therapy
- Re-Treatment With Revlimid Following A Short Treatment-Free Period May Result In A Second Response In Relapsed MDS Patients (ASH 2010)
- ASH 2010 Myelodysplastic Syndromes Update – Day 3 Evening & Day 4
- Revlimid Shows Survival Benefit In Subgroup Of Lower-Risk MDS Patients (ASH 2011)
- Revlimid Use In MDS May Not Increase Risk Of Additional Cancers (ASH 2011)